IMFINZI

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug IMFINZI contains one active pharmaceutical ingredient (API):

1 Durvalumab UNII 28X28X9OKV - DURVALUMAB

Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation. Read about Durvalumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IMFINZI Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FF03	Durvalumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11911X, 11915D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502318050033502, 502318050033602
Country: CA	Health Products and Food Branch	Identifier(s): 02468816
Country: EE	Ravimiamet	Identifier(s): 1769575, 1780602, 1780635, 1849899
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181322001, 1181322001IP, 1181322002, 1181322002IP
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 034118, 382578
Country: FR	Base de données publique des médicaments	Identifier(s): 63690956
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 358756, 358760
Country: HK	Department of Health Drug Office	Identifier(s): 65928, 65929
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8291, 8292
Country: IT	Agenzia del Farmaco	Identifier(s): 047089014, 047089026
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291443A1023, 4291443A2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086422, 1086423
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 196029, 196037
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20513, 20514
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100411705
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64923001, W64923002
Country: SG	Health Sciences Authority	Identifier(s): 15569P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699786770805, 8699786770904
Country: US	FDA, National Drug Code	Identifier(s): 0310-4500, 0310-4611
Country: ZA	Health Products Regulatory Authority	Identifier(s): 54/30.1/0001, 54/30.1/0002